Using anti-PPAT polyclonal antibody (HPA036091) in liver cancer research

January, 2022 (State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China)

PPAT: A new prognostic biomarker for liver cancer.

Liver cancer remains a global health challenge, with an estimated incidence of 1 million cases by 2025. Hepatocellular carcinoma is the most common form of liver cancer, accounting for approximately 90% of cases.

Using our anti-PPAT polyclonal antibody (HPA036091) this study reports that in hepatocellular carcinoma tumor tissues the expression of PPAT is significantly higher than that in adjacent normal tissues. Hence, PPAT could be served as a new prognostic biomarker for patients with hepatocellular carcinoma.



Read the full study:

Anti-PPAT antibody: